Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.
OBJECTIVES: Autocrine and paracrine chemokine/chemokine receptor-based interactions promote non-small-cell-lung-cancer (NSCLC) carcinogenesis. CCL20/CCR6 interactions are involved in prostatic and colonic malignancy pathogenesis. The expression and function of CCL20/CCR6 and its related Th-17 type i...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3174223?pdf=render |
id |
doaj-92051df2fab7467db6dcba7266ebef30 |
---|---|
record_format |
Article |
spelling |
doaj-92051df2fab7467db6dcba7266ebef302020-11-25T01:42:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0169e2485610.1371/journal.pone.0024856Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.Sophie KirshbergUzi IzharGail AmirJonathan DemmaFiona VerneaKatia BeiderZippora ShlomaiHanna WaldGideon ZamirOz M ShapiraAmnon PeledOri WaldOBJECTIVES: Autocrine and paracrine chemokine/chemokine receptor-based interactions promote non-small-cell-lung-cancer (NSCLC) carcinogenesis. CCL20/CCR6 interactions are involved in prostatic and colonic malignancy pathogenesis. The expression and function of CCL20/CCR6 and its related Th-17 type immune response in NSCLC is not yet defined. We sought to characterize the role of the CCL20/CCR6/IL-17 axis in NSCLC tumor growth. METHODS: A specialized histopathologist blindly assessed CCL20/CCR6 expression levels in 49 tissue samples of NSCLC patients operated in our department. Results were correlated to disease progression. Colony assays, ERK signaling and chemokine production were measured to assess cancer cell responsiveness to CCL20 and IL-17 stimulation. RESULTS: CCL20 was highly expressed in the majority (38/49, 77.5%) of tumor samples. Only a minority of samples (8/49, 16.5%) showed high CCR6 expression. High CCR6 expression was associated with a shorter disease-free survival (P = 0.008) and conferred a disease stage-independent 4.87-fold increased risk for disease recurrence (P = 0.0076, CI 95% 1.52-15.563). Cancerous cell colony-forming capacity was increased by CCL20 stimulation; this effect was dependent in part on ERK phosphorylation and signaling. IL-17 expression was detected in NSCLC; IL-17 potentiated the production of CCL20 by cancerous cells. CONCLUSION: Our findings suggest that the CCL20/CCR6 axis promotes NSCLC disease progression. CCR6 is identified as a potential new prognostic marker and the CCL20/CCR6/IL-17 axis as a potential new therapeutic target. Larger scale studies are required to consolidate these observations.http://europepmc.org/articles/PMC3174223?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sophie Kirshberg Uzi Izhar Gail Amir Jonathan Demma Fiona Vernea Katia Beider Zippora Shlomai Hanna Wald Gideon Zamir Oz M Shapira Amnon Peled Ori Wald |
spellingShingle |
Sophie Kirshberg Uzi Izhar Gail Amir Jonathan Demma Fiona Vernea Katia Beider Zippora Shlomai Hanna Wald Gideon Zamir Oz M Shapira Amnon Peled Ori Wald Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE |
author_facet |
Sophie Kirshberg Uzi Izhar Gail Amir Jonathan Demma Fiona Vernea Katia Beider Zippora Shlomai Hanna Wald Gideon Zamir Oz M Shapira Amnon Peled Ori Wald |
author_sort |
Sophie Kirshberg |
title |
Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. |
title_short |
Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. |
title_full |
Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. |
title_fullStr |
Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. |
title_full_unstemmed |
Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. |
title_sort |
involvement of ccr6/ccl20/il-17 axis in nsclc disease progression. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
OBJECTIVES: Autocrine and paracrine chemokine/chemokine receptor-based interactions promote non-small-cell-lung-cancer (NSCLC) carcinogenesis. CCL20/CCR6 interactions are involved in prostatic and colonic malignancy pathogenesis. The expression and function of CCL20/CCR6 and its related Th-17 type immune response in NSCLC is not yet defined. We sought to characterize the role of the CCL20/CCR6/IL-17 axis in NSCLC tumor growth. METHODS: A specialized histopathologist blindly assessed CCL20/CCR6 expression levels in 49 tissue samples of NSCLC patients operated in our department. Results were correlated to disease progression. Colony assays, ERK signaling and chemokine production were measured to assess cancer cell responsiveness to CCL20 and IL-17 stimulation. RESULTS: CCL20 was highly expressed in the majority (38/49, 77.5%) of tumor samples. Only a minority of samples (8/49, 16.5%) showed high CCR6 expression. High CCR6 expression was associated with a shorter disease-free survival (P = 0.008) and conferred a disease stage-independent 4.87-fold increased risk for disease recurrence (P = 0.0076, CI 95% 1.52-15.563). Cancerous cell colony-forming capacity was increased by CCL20 stimulation; this effect was dependent in part on ERK phosphorylation and signaling. IL-17 expression was detected in NSCLC; IL-17 potentiated the production of CCL20 by cancerous cells. CONCLUSION: Our findings suggest that the CCL20/CCR6 axis promotes NSCLC disease progression. CCR6 is identified as a potential new prognostic marker and the CCL20/CCR6/IL-17 axis as a potential new therapeutic target. Larger scale studies are required to consolidate these observations. |
url |
http://europepmc.org/articles/PMC3174223?pdf=render |
work_keys_str_mv |
AT sophiekirshberg involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT uziizhar involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT gailamir involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT jonathandemma involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT fionavernea involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT katiabeider involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT zipporashlomai involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT hannawald involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT gideonzamir involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT ozmshapira involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT amnonpeled involvementofccr6ccl20il17axisinnsclcdiseaseprogression AT oriwald involvementofccr6ccl20il17axisinnsclcdiseaseprogression |
_version_ |
1725035959836213248 |